ArQule’s ARQ 197 Stage 1 clinical trial results in colorectal tumor presented at ASCO 2011 ArQule, Inc. today announced the demonstration of Phase 1 results of a scientific trial among patients with metastatic colorectal cancer treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with cetuximab and irinotecan questions . ARQ 197 is usually under advancement by Daiichi Sankyo Co., Ltd. And ArQule. Among nine patients treated, one acquired a comprehensive response, two got partial responses and five experienced steady disease. The systemic exposure of ARQ 197 with this combination routine was consistent with previous observations, and no dose-limiting toxicities were observed.
Aradigm to present Phase 1 research of inhaled liposomal ciprofloxacin in 2010 ERS Congress Aradigm Corporation today announced it really is presenting data about September 22, 2010, from its Phase 1 studies in the ERS Annual Congress in Barcelona, Spain. The podium demonstration elaborates on the pharmacokinetic parameters of ciprofloxacin in the blood and sputum samples that were observed in the healthy volunteers and non-cystic fibrosis bronchiectasis sufferers.5 hours for the formulations ARD-3100 and ARD-3150, supporting dosing once-daily. The treatments led to high concentrations of ciprofloxacin in the sputum of non-CF bronchiectasis patients. ARD-3150 offered sustained ciprofloxacin levels comparable to ARD-3100 but it also exhibited an early spike of ciprofloxacin concentration that could have additional therapeutic benefits.